Childrens Loratadine Odt
Loratadine
Walgreen Co.
Human Otc Drug
NDC 0363-4020Childrens Loratadine Odt also known as Loratadine is a human otc drug labeled by 'Walgreen Co.'. National Drug Code (NDC) number for Childrens Loratadine Odt is 0363-4020. This drug is available in dosage form of Tablet, Orally Disintegrating. The names of the active, medicinal ingredients in Childrens Loratadine Odt drug includes Loratadine - 10 mg/1 . The currest status of Childrens Loratadine Odt drug is Active.
Drug Information:
| Drug NDC: | 0363-4020 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Childrens Loratadine Odt |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Loratadine |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Walgreen Co. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Tablet, Orally Disintegrating |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | LORATADINE - 10 mg/1
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | ORAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | ANDA |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 11 Apr, 2018 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 15 Jan, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | ANDA208477 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | WALGREEN CO.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 311373
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | 7AJO3BO7QN
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 0363-4020-84 | 3 BLISTER PACK in 1 CARTON (0363-4020-84) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK | 11 Apr, 2018 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose antihistamine
Product Elements:
Childrens loratadine odt loratadine loratadine loratadine aspartame crospovidone (120 .mu.m) mannitol microcrystalline cellulose peppermint starch, corn sodium stearyl fumarate white to off-white biconvex k;9
Indications and Usage:
Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat
Warnings:
Warnings
Do Not Use:
Warnings
When Using:
When using this product do not take more than directed. taking more than directed may cause drowsiness.
Dosage and Administration:
Directions place 1 tablet on tongue; tablet disintegrates, with or without water adults and children 6 years and over 1 tablet daily; not more than 1 tablet in 24 hours children under 6 years of age ask a doctor consumers with liver or kidney disease ask a doctor
Stop Use:
Stop use and ask a doctor if an allergic reaction to this product occurs. seek medical help right away.
Package Label Principal Display Panel:
Package label-principal display panel - 10 mg, blister carton 30 (3 x 10) orally disintegrating tablets ndc 0363-4020-84 walgreens compare to the active ingredient in claritin ® reditabs ® junior's allergy relief loratadine orally disintegrating tablets usp 10 mg / antihistamine dissolvable tablet non-drowsy * 24 hour melts in mouth with no water needed 24-hour relief of sneezing, runny nose, itchy, watery eyes & itchy throat or nose indoor & outdoor allergies ages 6 years & older 30 orally disintegrating tablets actual size *when taken as directed. see drug facts panel. package label-principal display panel - 10 mg, blister carton 30 (3 x 10) orally disintegrating tablets
Further Questions:
Questions or comments? call 1-855-274-4122 distributed by: walgreen co. 200 wilmot rd., deerfield, il 60015 walgreens 100% satisfaction guaranteed walgreens.com ©2021 walgreen co. made in india code: ts/drugs/22/2009